证券代码：688520 证券简称：神州细胞 公告编号：2025-040 北京神州细胞生物技术集团股份公司 关于向特定对象发行股票申请文件的 审核问询函回复的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"）于 2025 年 9 月 5 日收到上海证券交易所（以下简称"上交所"）出具的《关于北京神州细胞生物 技术集团股份公司向特定对象发行股票申请文件的审核问询函》（上证科审（再 融资）〔2025〕114 号）（以下简称"审核问询函"）。 公司会同相关中介机构对审核问询函所列问题进行了认真研究和逐项落实， 并按审核问询函要求对有关问题进行了说明和论证分析，同时结合 2025 年半年 度财务报告，对申请文件进行了相应更新，现根据要求对审核问询函回复及相关 申请文件进行公开披露，具体内容详见公司同日披露的《关于北京神州细胞生物 技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复报告》等文 件。 公司本次向特定对象发行股票事项尚需通过上交所审核，并获得中国证券监 ...

Group 1: Innovation Qizhi (02121.HK) - The report initiates coverage on Innovation Qizhi, projecting revenues of 1.471 billion, 1.729 billion, and 2.008 billion CNY for 2025-2027, representing year-on-year growth of 20.4%, 17.5%, and 16.2% respectively [1][7] - The net profit attributable to the parent company is expected to be -170 million, -127 million, and -61 million CNY for the same period, with adjusted net profit turning positive in 2026 [1][7] - The target market capitalization for 2025 is estimated at 5.642 billion HKD, corresponding to a target price of 10.01 HKD, with a "Buy" rating assigned [1][7] Group 2: Shenzhou Cell (688520.SH) - The company is expected to generate revenues of 2.194 billion, 2.543 billion, and 3.021 billion CNY from 2025 to 2027, with a year-on-year decline of 12.7% in 2025, followed by growth of 15.9% and 18.8% in the subsequent years [2][12] - The first half of 2025 saw revenues of 972 million CNY, a decrease of 25.5%, primarily due to regional policy impacts and price reductions in the market [10][11] - The company maintains a "Buy" rating, considering the potential catalysts from its innovative pipeline despite short-term sales pressure [2][12] Group 3: Jiangshan Oupai (603208.SH) - The company reported revenues of 868 million and 466 million CNY for the first half and second quarter of 2025, reflecting declines of 39.82% and 42.9% year-on-year [14][15] - The net profit attributable to the parent company was 10 million and 7 million CNY for the same periods, showing significant declines of 90.39% and 91.3% respectively [14][15] - The company is transitioning its business model from heavy asset to light asset and is expected to gradually improve performance as strategic adjustments take effect [16] Group 4: Swine Industry Dynamics - In August 2025, listed pig companies reported an output of 16.6036 million heads, a year-on-year increase of 29.11% and a month-on-month increase of 6.86% [5][18] - The total revenue for listed pig companies in August was 24.859 billion CNY, a decrease of 14.21% year-on-year, while cumulative revenue from January to August reached 205.332 billion CNY, up 11.57% year-on-year [5][19] - The average selling price of pigs in August decreased by 31.03% year-on-year, attributed to an oversupply in the market despite a slight month-on-month increase [20]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by over 20% in the next 6-12 months [3][11][6]. Core Insights - The company's revenue for the first half of 2025 was 972 million yuan, a decrease of 25.50% compared to the previous period, primarily due to regional price reductions and healthcare cost controls affecting the market for its core product, Anjain® [1][6]. - The company is focusing on expanding its market presence and ensuring competitive pricing in key provinces, aiming for a recovery in Anjain® sales [2][3]. - The company has made significant investments in R&D, totaling 388 million yuan, and has a robust pipeline with 13 products in clinical research stages, including innovative therapies targeting various cancers and autoimmune diseases [2][3]. Financial Summary - Revenue projections for 2025-2027 are estimated at 2.194 billion yuan, 2.543 billion yuan, and 3.021 billion yuan, reflecting a year-on-year growth of -12.7%, 15.9%, and 18.8% respectively [4][3]. - The net profit for 2025 is projected to be -33 million yuan, with a significant recovery expected in subsequent years, reaching 230 million yuan by 2027 [4][3]. - The company reported a gross margin of 94.79% in the first half of 2025, with expenses for sales, management, R&D, and finance at 43.4%, 8.8%, 39.0%, and 4.5% respectively [1][6].

Company Overview - Shenzhou Cell is located in Beijing Economic and Technological Development Zone and was established on April 23, 2007. The company went public on June 22, 2020. Its main business involves the research and industrialization of biopharmaceutical products for malignant tumors, autoimmune diseases, infectious diseases, and genetic diseases [1][2]. Stock Performance - As of September 10, Shenzhou Cell's stock price decreased by 2.00% to 59.66 CNY per share, with a trading volume of 1.19 billion CNY and a turnover rate of 0.44%. The total market capitalization is 26.569 billion CNY [1]. - Year-to-date, Shenzhou Cell's stock has increased by 64.67%, but it has seen a decline of 6.02% over the last five trading days and 8.30% over the last 20 days. In contrast, it has risen by 31.12% over the last 60 days [1]. Financial Performance - For the first half of 2025, Shenzhou Cell reported a revenue of 972 million CNY, a year-on-year decrease of 25.50%. The net profit attributable to the parent company was -33.771 million CNY, representing a year-on-year decrease of 126.87% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for Shenzhou Cell was 9,754, a decrease of 12.74% from the previous period. The average number of tradable shares per shareholder increased by 14.60% to 45,656 shares [2]. - Notably, new institutional shareholders include Southern CSI 500 ETF, which holds 2.7025 million shares, and China Europe Medical Health Mixed A, which holds 2.3579 million shares. Hong Kong Central Clearing Limited and China Merchants National Bio-Medical Index A have exited the top ten shareholders list [2]. Market Activity - Shenzhou Cell has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on July 4, where it recorded a net purchase of 87.5322 million CNY. The total purchases amounted to 489 million CNY, accounting for 30.04% of the total trading volume, while total sales reached 402 million CNY, making up 24.66% of the total trading volume [1]. Industry Classification - Shenzhou Cell belongs to the pharmaceutical and biological sector, specifically under the subcategory of biological products, and is associated with concepts such as biomedicine, innovative drugs, vaccines, and anti-cancer drugs [2].

（文章来源：证券日报） 证券日报网讯 9月8日晚间，神州细胞发布公告称，公司计划于2025年9月16日（星期二）15：00-17： 00参加由上海证券交易所主办的2025年半年度科创板创新药行业集体业绩说明会。 ...

证券代码：688520 证券简称：神州细胞 公告编号：2025-039 北京神州细胞生物技术集团股份公司 关于参加 2025 年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、 参加人员 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 ir@sinocelltech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告。为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 16 日 （星期二） 15:00-17:00 参加由上海证券交易所主办的 2025 年半年度科创板创新药行业集体 业绩说明会，就投资者关心 ...

Company Overview - Shenzhou Cell is located in Beijing Economic and Technological Development Zone and was established on April 23, 2007. The company went public on June 22, 2020. Its main business involves the research and industrialization of biopharmaceutical products for malignant tumors, autoimmune diseases, infectious diseases, and genetic diseases [1][2]. Stock Performance - As of September 8, Shenzhou Cell's stock price was 61.74 CNY per share, with a market capitalization of 27.495 billion CNY. The stock has increased by 70.41% year-to-date but has seen a decline of 6.27% over the last five trading days and 5.65% over the last twenty days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on July 4, where it recorded a net buy of 87.5322 million CNY [1]. Financial Performance - For the first half of 2025, Shenzhou Cell reported a revenue of 972 million CNY, a decrease of 25.50% year-on-year. The net profit attributable to the parent company was -33.7711 million CNY, reflecting a significant decline of 126.87% year-on-year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders was 9,754, a decrease of 12.74% from the previous period. The average number of circulating shares per person increased by 14.60% to 45,656 shares [2]. - Notable changes in institutional holdings include the entry of new shareholders such as Southern CSI 500 ETF and China Europe Medical Health Mixed A, while Hong Kong Central Clearing Limited and China Merchants National Bio-Medical Index A exited the top ten circulating shareholders [2]. Industry Classification - Shenzhou Cell belongs to the pharmaceutical and biotechnology sector, specifically in the subcategory of biopharmaceuticals, with a focus on innovative drugs, vaccines, biomedicine, anti-cancer drugs, and cell therapy [2].

Group 1 - The electric power equipment industry has become a favorite among investors in September, with a net buying amount of 1.144 billion yuan, leading the market [1][2] - 26 stocks, including Jianghuai Automobile, saw over 100 million yuan in financing on a single day, indicating significant institutional interest [2] - The current market activity may reflect a strategic maneuver by institutions rather than genuine enthusiasm for the new energy sector [1][9] Group 2 - Historical context shows that market fluctuations often coincide with institutional strategies, such as the significant market movements in the second quarter of 2025 [3][4] - Institutions may engage in "smashing the market" to accumulate shares when they find their positions insufficient, leading to sudden market drops that are misinterpreted as external shocks [4][12] - The electric power equipment sector's current financing activity raises questions about whether it is a genuine value discovery or a prelude to another institutional shakeout [9][12] Group 3 - Case studies of Huadong Medicine and Shenzhou Cell illustrate the difference between genuine market adjustments and strategic institutional actions, with the latter often leading to significant price movements [6][8] - Data analysis reveals that Shenzhou Cell experienced notable institutional buying during its adjustment, while Huadong Medicine did not, resulting in divergent outcomes when the market rebounded [8] - The electric power equipment industry's recent activity may mirror past instances where institutions manipulated market perceptions to their advantage [12]

Group 1 - The core viewpoint of the news is that Shenzhou Cell has experienced significant stock price fluctuations and changes in shareholder structure, reflecting its performance in the biopharmaceutical industry [1][2]. - As of September 5, Shenzhou Cell's stock price increased by 2.04% to 62.62 CNY per share, with a total market capitalization of 27.887 billion CNY [1]. - The company has seen a year-to-date stock price increase of 72.84%, but it has experienced a decline of 1.39% over the last five trading days and 5.55% over the last twenty days [1]. Group 2 - Shenzhou Cell operates in the biopharmaceutical sector, focusing on the research and commercialization of biological drugs for various diseases, including cancer and autoimmune diseases [1][2]. - For the first half of 2025, Shenzhou Cell reported a revenue of 972 million CNY, a year-on-year decrease of 25.50%, and a net profit attributable to shareholders of -33.771 million CNY, a decline of 126.87% [2]. - The number of shareholders decreased by 12.74% to 9,754 as of June 30, 2025, while the average circulating shares per person increased by 14.60% to 45,656 shares [2].

Group 1 - The core viewpoint of the news is that Shenzhou Cell's stock has experienced fluctuations, with a notable year-to-date increase of 71.71%, but recent declines in the short term [1][2] - As of September 4, Shenzhou Cell's stock price was 62.21 yuan per share, with a total market capitalization of 27.704 billion yuan [1] - The company has seen significant trading activity, with a net outflow of main funds amounting to 5.9535 million yuan on September 4, and notable buying and selling volumes from large orders [1] Group 2 - Shenzhou Cell operates in the pharmaceutical and biotechnology sector, focusing on the research and commercialization of biological drugs for various diseases, including cancer and autoimmune diseases [1][2] - For the first half of 2025, Shenzhou Cell reported a revenue of 972 million yuan, a year-on-year decrease of 25.50%, and a net profit attributable to shareholders of -33.7711 million yuan, reflecting a significant decline of 126.87% [2] - The number of shareholders decreased by 12.74% to 9,754 as of June 30, 2025, while the average circulating shares per person increased by 14.60% [2]